Literature DB >> 20432331

What treatment should we use if drugs fail for OAB; and, what really works after drugs?

J L H R Bosch1, C Kelleher, P E V van Kerrebroeck, B Schurch.   

Abstract

AIMS: To determine (using structured brain storm sessions), which treatments should be used if drugs fail for OAB and to determine priority research questions in relation to this issue.
METHODS: A frame work for discussion was prepared by the chairman of the session; this included a brief summary of the currently existing evidence. Several experts had been asked to prepare a presentation of their personal treatment algorithm and to identify the [lack of] evidence for such an algorithm. These presentations were summarized by the chairman. Next, this summary was discussed with a large group of experts and opinion leaders and audio-recorded. The proceedings of this process are the basis for this manuscript.
RESULTS: The structured sessions resulted in detailed statements about: possible reasons for failure of conservative treatment, the evaluation of outcomes of RCT's, the use of botulinum toxin A in refractory OAB patients, the relative place of neuromodulation or sacral nerve stimulation and botulinum toxin A in the treatment of refractory OAB.
CONCLUSIONS: A list of 10 unanswered questions and research topics was compiled. Additionally, 5 top priority research topics were identified. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20432331     DOI: 10.1002/nau.20906

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  3 in total

1.  Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.

Authors:  T A T Marcelissen; M S Rahnama'i; A Snijkers; B Schurch; P De Vries
Journal:  World J Urol       Date:  2016-06-07       Impact factor: 4.226

2.  Sacral neuromodulation outcomes for the treatment of refractory idiopathic detrusor overactivity stratified by indication: Lack of anticholinergic efficacy versus intolerability.

Authors:  Tanya Davis; Iryna Makovey; Michael L Guralnick; R Corey O'Connor
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

3.  The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty.

Authors:  Ahmed S El-Azab; Ahmed M Moeen
Journal:  Arab J Urol       Date:  2013-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.